158 related articles for article (PubMed ID: 35908450)
1. Disease reactivation after fingolimod cessation in Multiple Sclerosis patients with pregnancy desire: A retrospective study.
Callens A; Leblanc S; Le Page E; Edan G; Jourdain A; Coustans M; Wiertlewski S; Laplaud D; Videt D; Lallement F; Leray E; Michel L
Mult Scler Relat Disord; 2022 Oct; 66():104066. PubMed ID: 35908450
[TBL] [Abstract][Full Text] [Related]
2. Rebound Syndrome in Patients With Multiple Sclerosis After Cessation of Fingolimod Treatment.
Hatcher SE; Waubant E; Nourbakhsh B; Crabtree-Hartman E; Graves JS
JAMA Neurol; 2016 Jul; 73(7):790-4. PubMed ID: 27135594
[TBL] [Abstract][Full Text] [Related]
3. Disease Reactivation After Cessation of Disease-Modifying Therapy in Patients With Relapsing-Remitting Multiple Sclerosis.
Roos I; Malpas C; Leray E; Casey R; Horakova D; Havrdova EK; Debouverie M; Patti F; De Seze J; Izquierdo G; Eichau S; Edan G; Prat A; Girard M; Ozakbas S; Grammond P; Zephir H; Ciron J; Maillart E; Moreau T; Amato MP; Labauge P; Alroughani R; Buzzard K; Skibina O; Terzi M; Laplaud DA; Berger E; Grand'Maison F; Lebrun-Frenay C; Cartechini E; Boz C; Lechner-Scott J; Clavelou P; Stankoff B; Prevost J; Kappos L; Pelletier J; Shaygannejad V; Yamout BI; Khoury SJ; Gerlach O; Spitaleri DLA; Van Pesch V; Gout O; Turkoglu R; Heinzlef O; Thouvenot E; McCombe PA; Soysal A; Bourre B; Slee M; Castillo-Trivino T; Bakchine S; Ampapa R; Butler EG; Wahab A; Macdonell RA; Aguera-Morales E; Cabre P; Ben NH; Van der Walt A; Laureys G; Van Hijfte L; Ramo-Tello CM; Maubeuge N; Hodgkinson S; Sánchez-Menoyo JL; Barnett MH; Labeyrie C; Vucic S; Sidhom Y; Gouider R; Csepany T; Sotoca J; de Gans K; Al-Asmi A; Fragoso YD; Vukusic S; Butzkueven H; Kalincik T;
Neurology; 2022 Oct; 99(17):e1926-e1944. PubMed ID: 35977837
[TBL] [Abstract][Full Text] [Related]
4. Ocrelizumab versus fingolimod after natalizumab cessation in multiple sclerosis: an observational study.
Bigaut K; Kremer L; Fabacher T; Ahle G; Goudot M; Fleury M; Gaultier C; Courtois S; Collongues N; de Seze J
J Neurol; 2022 Jun; 269(6):3295-3300. PubMed ID: 34982200
[TBL] [Abstract][Full Text] [Related]
5. Disease Reactivation after Fingolimod Discontinuation in Pregnant Multiple Sclerosis Patients.
Bianco A; Lucchini M; Totaro R; Fantozzi R; De Luca G; Di Lemme S; Presicce G; Evangelista L; Di Tommaso V; Pastorino R; De Fino C; De Arcangelis V; Centonze D; Mirabella M
Neurotherapeutics; 2021 Oct; 18(4):2598-2607. PubMed ID: 34494237
[TBL] [Abstract][Full Text] [Related]
6. Multiple Sclerosis Relapses Following Cessation of Fingolimod.
Malpas CB; Roos I; Sharmin S; Buzzard K; Skibina O; Butzkueven H; Kappos L; Patti F; Alroughani R; Horakova D; Havrdova EK; Izquierdo G; Eichau S; Hodgkinson S; Grammond P; Lechner-Scott J; Kalincik T;
Clin Drug Investig; 2022 Apr; 42(4):355-364. PubMed ID: 35303292
[TBL] [Abstract][Full Text] [Related]
7. A short washout period from fingolimod to anti-CD20 therapy is safe and decreases the risk of reactivation.
Gassama S; Garmendia A; Lejeune FX; Boudot de la Motte M; Louapre C; Papeix C; Maillart E; Roux T
Rev Neurol (Paris); 2023 Nov; 179(9):1035-1038. PubMed ID: 37633735
[TBL] [Abstract][Full Text] [Related]
8. Frequency and risk factors of rebound after fingolimod discontinuation - A retrospective study.
Maunula A; Atula S; Laakso SM; Tienari PJ
Mult Scler Relat Disord; 2024 Jan; 81():105134. PubMed ID: 37980790
[TBL] [Abstract][Full Text] [Related]
9. Risk of fingolimod rebound after switching to cladribine or rituximab in multiple sclerosis.
Nygaard GO; Torgauten H; Skattebøl L; Høgestøl EA; Sowa P; Myhr KM; Torkildsen Ø; Celius EG
Mult Scler Relat Disord; 2022 Jun; 62():103812. PubMed ID: 35462167
[TBL] [Abstract][Full Text] [Related]
10. Recurrence of disease activity during pregnancy after cessation of fingolimod in multiple sclerosis.
Meinl I; Havla J; Hohlfeld R; Kümpfel T
Mult Scler; 2018 Jun; 24(7):991-994. PubMed ID: 28920764
[TBL] [Abstract][Full Text] [Related]
11. A Prospective, Observational Study Assessing Effectiveness, Safety, and QoL of Greek Patients with Multiple Sclerosis Under Treatment with Fingolimod.
Mitsikostas DD; Orologas A; Dardiotis E; Fakas N; Doskas T; Karageorgiou K; Maltezou M; Iliopoulos I; Vikelis M; Grigoriadis N
Adv Ther; 2023 May; 40(5):2217-2233. PubMed ID: 36897520
[TBL] [Abstract][Full Text] [Related]
12. Evidence of disease activity during pregnancy and post-partum in MS patients treated with high-efficacy therapies.
Sahloul O; Louapre C; Beigneux Y; Lubetzki C; Maillart E; Roux T
Mult Scler Relat Disord; 2024 May; 85():105557. PubMed ID: 38520946
[TBL] [Abstract][Full Text] [Related]
13. Neurological update: treatment escalation in multiple sclerosis patients refractory to fingolimod-potentials and risks of subsequent highly active agents.
Korsen M; Pfeuffer S; Rolfes L; Meuth SG; Hartung HP
J Neurol; 2022 May; 269(5):2806-2818. PubMed ID: 34999925
[TBL] [Abstract][Full Text] [Related]
14. Cryptococcal meningitis in a multiple sclerosis patient treated with Fingolimod: a case report and review of imaging findings.
Chong I; Wang KY; Lincoln CM
Clin Imaging; 2019; 54():53-56. PubMed ID: 30544079
[TBL] [Abstract][Full Text] [Related]
15. Rebound activity after fingolimod cessation: A case - control study.
Barboza A; Gaitán MI; Alonso R; Ysrraelit MC; Luetic G; Liwacki S; Patrucco L; Halfon MJ; Burgos M; Mainella C; Pierdabuena R; Recchia L; Steinberg J; Tkachuk VA; Zanga G; Carra A; Chertcoff A; Fernandez Liguori N; Lazaro L; Menichini ML; Miguez J; Orzuza G; Palavecino A; Pappolla A; Pigretti S; Pita C; Ruiz E; Silva B; Zentil G
Mult Scler Relat Disord; 2022 Jan; 57():103329. PubMed ID: 35158443
[TBL] [Abstract][Full Text] [Related]
16. Fingolimod-related atrioventricular block in paediatric age group with multiple sclerosis: two case reports.
Kum YE; Pamukçu Ö; Canpolat M
Cardiol Young; 2023 Nov; 33(11):2384-2386. PubMed ID: 37170775
[TBL] [Abstract][Full Text] [Related]
17. Effect of fingolimod therapy on quantitative macular changes among patients with relapsing-remitting multiple sclerosis: a four-year follow-up study from Oman.
Al-Rashdi AA; Sabt BI; Al-Mujaini AS
BMC Ophthalmol; 2022 Dec; 22(1):470. PubMed ID: 36471269
[TBL] [Abstract][Full Text] [Related]
18. Factors Predictive of Severe Multiple Sclerosis Disease Reactivation After Fingolimod Cessation.
Uygunoglu U; Tutuncu M; Altintas A; Saip S; Siva A
Neurologist; 2018 Jan; 23(1):12-16. PubMed ID: 29266038
[TBL] [Abstract][Full Text] [Related]
19. Clinical activity after fingolimod cessation: disease reactivation or rebound?
Frau J; Sormani MP; Signori A; Realmuto S; Baroncini D; Annovazzi P; Signoriello E; Maniscalco GT; La Gioia S; Cordioli C; Frigeni B; Rasia S; Fenu G; Grasso R; Sartori A; Lanzillo R; Stromillo ML; Rossi S; Forci B; Cocco E;
Eur J Neurol; 2018 Oct; 25(10):1270-1275. PubMed ID: 29851435
[TBL] [Abstract][Full Text] [Related]
20. Hepatitis C virus (HCV) reactivation during fingolimod treatment for relapsing and remitting multiple sclerosis.
Tagawa A; Ogawa T; Tetsuka S; Otsuka M; Hashimoto R; Kato H; Ando K; Tanabe H
Mult Scler Relat Disord; 2016 Sep; 9():155-7. PubMed ID: 27645365
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
